Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer

International Journal of Cancer

Volumn 89, Issue 1, 2000, Pages 81-86

  Zalcman, Gérard ^a,b   Trédaniel, Jean ^a   Schlichtholz, Beata ^b   Urban, Thierry ^c   Milleron, Bernard ^d   Lubin, Richard ^a   Meignin, Véronique ^a   Couderc, Louis Jean ^e   Hirsch, Albert ^a   Soussi, Thierry ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUT CURIE   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d HÔPITAL TENON   (France)

^e Service ORL et Chirurgie Cervicofaciale   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CANCER STAGING; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

BIOLOGICAL MARKERS; CARCINOMA, SMALL CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRECIPITIN TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034688182     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000120)89:1<81::AID-IJC13>3.0.CO;2-I     Document Type: Article

References (28)

1. ALBAIN, K.S., CROWLEY, J.J. and LIVINGSTON, R.B., Long-term survival and toxicity in small cell lung cancer. Chest, 99, 1425-32 (1991).
2. BENNETT, W.P. and 15 others, p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res., 53, 4817-4822 (1993).
3. BERGH, J., NORBERG, T., SJÖGREN, S., LINDGREN, A. and HOLMBERG, L., Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature (Med.), 1, 1029-1034 (1995).
4. BEROUD, C. and SOUSSI, T., p53 gene mutation: software and database. Nucleic Acids Res., 26, 200-204 (1998).
5. BOURHIS, J. and 12 others, Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J. nat. Cancer Inst., 88, 1228-1233 (1996).
6. D'AMICO, D., CARBONE, D., MITSUDOMI, T., NAU, M., FEDORKO, J., RUSSELL, E., JOHNSON, B., BUCHHAGEN, D., BODNER, S., PHELPS, R., GAZDAR, A. and MINNA, J.D., High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene, 7, 339-346 (1992).
7. DENISSENKO, M.F., PAO, A., TANG, M.S. and PFEIFER, G.P., Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science, 274, 430-432 (1996).
8. FRITSCHE, M., HAESSLER, C. and BRANDNER, G., Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene, 8, 307-318 (1993).
9. GOH, H.S., YAO, J. and SMITH, D.R., p53 point mutation and survival in colorectal cancer patients. Cancer Res., 55, 5217-5221 (1995).
10. GREENBLATT, M.S., BENNETT, W.P., HOLLSTEIN, M. and HARRIS, C.C., Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878 (1994).
11. GUINEE, D.G. and 15 others, Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis, 16, 993-1002 (1995).
12. HOUBIERS, J.G.A., VAN DER BURG, S.H., VAN DE WATERING, L.M.G., TOLLENAAR, R.A.E.M., BRAND, A., VAN DE VELDE, C.J.H. and MELIEF, C.J.M., Antibodies against p53 are associated with poor prognosis of colorectal cancer. Brit. J. Cancer, 72, 637-641 (1995).
13. JORGENSEN, L.G.M., OSTERLIND, K., GENOLLA, J., GOMM, S.A., HERNANDEZ, J.R., JOHNSON, P.W.M., LOBER, J., SPLINTER, T.A.W. and SZTUMOWICZ, M., Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Brit. J. Cancer, 74, 463-467 (1996).
14. LEVINE, A.J., p53, the cellular gatekeeper for growth and division. Cell, 88, 323-331 (1997).
15. LOWE, S.W., RULEY, H.E., JACKS, T. and HOUSMAN, D.E., p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967 (1993).
16. LUBIN, R., SCHLICHTHOLZ, B., TEILLAUD, J.L., GARAY, E., BUSSEL, A., WILD, C. and SOUSSI, T., p53 antibodies in patients with various types of cancer: assay, identification and characterization. Clin. Cancer Res., 1, 1463-1469 (1995a).
17. LUBIN, R., ZALCMAN, G., BOUCHET, L., TREDANIEL, J., LEGROS, Y., CAZALS, D., HIRSH, A. AND SOUSSI, T., Serum p53 antibodies as early markers of lung cancer. Nature (Med.). 1, 701-702 (1995b).
18. PEYRAT, J.P., BONNETERRE, J., LUBIN, R., VANLEMMENS, L., FOURNIER, J. and SOUSSI, T., Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet, 345, 621-622 (1995).
19. RALHAN, R., NATH, N., AGARWAL, S., MATHUR, M., WASYLYK, B. and SHUKLA, N.K., Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin. Cancer Res., 4, 2147-52 (1998).
20. ROSENFELD, M.R., MALATS, N., SCHRAMM, L., GRAUS, F., CARDENAL, F., VINOLAS, N., ROSELL, R., TORA, M., REAL, F.X., POSNER, J.B. and DALMAU, J., Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J. nat. Cancer Inst., 89, 381-385 (1997).
21. SCHLICHTHOLZ, B., TRÉDANIEL, J., LUBIN, R., ZALCMAN, G., HIRSCH, A. and SOUSSI, T., Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Brit. J. Cancer. 69, 809-816 (1994).
22. SOUSSI, T., The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy, Immunol. Today, 17, 354-356 (1996).
23. TAKAHASHI, T., TAKAHASHI, T., SUZUKI, H., HIDA, T., SEKIDO, Y., ARIYOSHI, Y. and UEDA, R., The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene, 6, 1775-1778 (1991).
24. TENAUD, C., NEGOESCU, A., LABATMOLEUR, F., LEGROS, Y., SOUSSI, T. and BRAMBILLA, E., Methods in pathology - p53 immunolabeling in archival paraffin-embedded tissues: optimal protocol based on microwave heating for eight antibodies on lung carcinomas. Mod. Pathol., 7, 853-859 (1994).
25. TRIVERS, G.E., DE BENEDETTI, V.M.G., CAWLEY, H.I., CARON, G., HARRINGTON, A.M., BENNET, W.P., JETT, J.R., COLBY, T.V., TAZELAAR, H., PAIROLERO, P., MILLER, R.D. and HARRIS, C.C., Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin. Cancer Res., 2, 1767-1775 (1996).
26. WILD, C.P., RIDANPAA, M., ANTTILA, S., LUBIN, R., SOUSSI, T., HUSGAFVEL-PURSIAINEN, K. and VAINIO, H., p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int. J. Cancer, 64, 176-181 (1995).
27. WINTER, S.F., MINNA, J.D., JOHNSON, B.E., TAKAHASHI, T., GAZDAR, A.F. and CARBONE, D.P., Development of Antibodies Against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res., 52, 4168-4174 (1992).
28. ZALCMAN, G., SCHLICHTHOLZ, B., TRÉDANIEL, J., URBAN, T., LUBIN, R., DUBOIS, I., MILLERON, B., HIRSH, A. and SOUSSI, T., Monitoring of p53 auto antibodies in lung cancer during therapy: relationship to response to treatment. Clin. Cancer Res., 4, 1359-1366 (1998).